The inhibitory effect of dopamine on aldosterone secretion was investigated in patients with different types of primary aldosteronism, six with idiopathic hyperaldosteronism (IHA) and four with dexamethasone-suppressible hyperaldosteronism (DSH), and in 10 patients with essential hypertension. The effects of 10 mg metoclopramide given intravenously, 10 mg bromocriptine given orally and 100 μg adrenocorticotrophic hormone given intravenously on plasma aldosterone and renin activities were investigated in all patients. Metoclopramide induced a rise in plasma aldosterone activity only in patients with IHA and not in those with DSH and essential hypertension. After bromocriptine plasma aldosterone concentrations decreased in patients with IHA only, and after adrenocorticotrophic hormone plasma aldosterone concentrations increased in patients with DSH only. Plasma renin activity was unaffected in all cases. These results provide evidence of increased endogenous dopaminergic inhibition of aldosterone secretion in IHA and of a blunted aldosterone response in both DSH and essential hypertension.
FraserRDopamine regulation of aldosterone secretion: an open question. J Endocrinol1987; 112: 179–181.
3.
SowersJRDopamine modulation of renin and aldosterone secretion: a review. J Hypertens1984; 2 (suppl 1): 67–73.
4.
FraserRConnellJMCInglisGThe role of dopamine in the control of corticosteroid secretion and metabolism. J Steroid Biochem1989; 32: 217–222.
5.
KuchelOBuuNTVecselPAre plasma aldosterone surges in primary aldosteronism due to a loss of an inhibitory dopaminergic control?J Clin Endocrinol Metab1980; 51: 337–344.
6.
GangulyAMeladaGALeutscherJAControl of plasma aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia. J Clin Endocrinol Metab1973; 37: 765–769.
OsIKjeldsenSEWestheimADecreased central dopaminergic activity in essential hypertension. J Hypertens1987; 5: 191–197.
9.
JungmannEAlthoffPHRosakCEndogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronism. Harm Metab Res1986; 18: 138–140.
10.
KhoTLVan HooffJPNievwenhuyzen KrusemanACEndogenous dopamine inhibits aldosterone secretion inadequately in primary aldosteronism. In: First European Congress of Endocrinology, Copenhagen (JensenJChristiansenC eds) 1987; p 186A.
11.
GniadekTCGrekinRRGrossMDHyperresponsiveness of aldosterone to metoclopramide in aldosteronism. Clin Endocrinol1982; 16: 475–481.
12.
GangulyAPrattJKWeinbergerMHDiffering effects of metoclopramide and adrenocorticotrophin in plasma aldosterone levels in glucocorticoid suppressive hyperaldosteronism and in other forms of hyperaldosteronism. J Clin Endocrinol Metab1983; 57: 388–392.
13.
GangulyAWeinbergerMHGuthrieGPAdrenal steroid responses to ACTH in glucocorticoid-suppressible aldosteronism. Hypertension1984; 6: 563–567.
14.
KemDCWeinbergerMHHigginsJRPlasma aldosterone response to ACTH in primary aldosteronism and in patients with low renin hypertension. J Clin Endocrinol Metab1978; 46: 552–560.
15.
LeeSMLightnerGWitteMDexamethasone suppressible hyperaldosteronism in a child with nephrosclerosis. Acta Endocrinol (Copenh)1982; 99: 251–255.
16.
GillJRBartterFCOverproduction of sodium-retaining steroids by the zona glomerulosa is adrenocorticotrophin-dependent and mediates hypertension in dexamethasone-suppressible aldosteronism. J Clin Endocrinol Metab1981; 53: 331–337.
17.
CareyRMThornerMOOrttEMDopaminergic inhibition of metoclopramide-induced aldosterone secretion in man: dissociation of responses to dopamine and bromocriptine. J Clin Invest1980; 66: 10–18.
18.
CareyRMThornerMOOrttEMEffects of metoclopramide and bromocriptine on the rennin–angiotensin–aldosterone system in man. Dopaminergic control of aldosterone. J Clin Invest1979; 63: 727–735.
19.
BirkhauserMRiondelAVallottonMBBromocriptine-induced modulation of plasma aldosterone response to acute stimulations. Acta Endocrinol (Copenh)1979; 91: 294–302.
20.
ManteroFGionMArmaniniDEffect of bromocriptine on plasma aldosterone in primary aldosteronism. Acta Endocrinol (Copenh)1977; 85 (suppl 212: 94A.
21.
HoganMJBrownRDHegstadRBromocriptine in primary aldosteronism. Lancet1980; ii: 89–90.
22.
WisgerhofMMellingerRCEffect of bromocriptine treatment on the aldosterone response to angiotensin II and adrenocorticotrophin in idiopathic hyperaldosteronism. J Clin Endocrinol Metab1985; 61: 192–195.
23.
KollochRKobayashiKDe QuattroVDopaminergic control of sympathetic tone and blood pressure: evidence in primary hypertension. Hypertension1980; 2: 390–394.
WitzgallHLorenzRVon WerderKDopamine reduces aldosterone and 18-hydroxycorticosterone response to angiotensin II in patients with essential low-renin hypertension and idiopathic hyperaldosteronism. Clin Sci1985; 68: 291–299.
26.
SternNSowersJRTuckMEnhanced response of plasma aldosterone to metoclopramide in essential hypertension. J Hypertens1984; 2: 209–214.
27.
KuchelOBuuNTHametPFree and conjugated dopamine in pheochromocytoma, primary aldosteronism and essential hypertension. Hypertension1979; 1: 267–273.
28.
SowersJRSollarsFBarrettJDEffect of L-dopa and bilateral nephrectomy on the aldosterone response to metoclopramide. Life Sci1980; 27: 497–501.
29.
BrownRDBillmannGEKemDCThe effect of metoclopramide and dopamine on plasma aldosterone in normal man and rhesus monkeys: a new model to study dopamine control of aldosterone secretion. J Clin Endocrinol Metab1982; 55: 828–832.
